From the Guidelines
I strongly advise against using Deviry (Duphaston) tablets for the treatment of Chronic Obstructive Pulmonary Disease (COPD), as they are not a standard or recommended medication for this condition. The medication Deviry, also known as Duphaston, is actually a progestin used in the treatment of various gynecological conditions, not COPD. According to the 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD 1, the recommended treatments for COPD include inhaled maintenance therapy with long-acting bronchodilators (LABDs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICS), among others.
Key points to consider in COPD treatment include:
- The alleviation of symptoms, particularly dyspnea, and improvement of health status as primary treatment goals
- The use of LABD maintenance therapy in all individuals with persistent symptoms, even mild, with COPD
- The recommendation for LAMA/LABA dual therapy in individuals with moderate to severe dyspnea and reduced health status
- The importance of preventing acute exacerbations of COPD (AECOPD) and the choice of therapy based on the risk of future AECOPD
It is essential to consult a healthcare provider for proper diagnosis and treatment of COPD, as medication regimens are individualized based on disease severity, symptoms, exacerbation history, and other health conditions. Never adjust medication without medical supervision, as proper treatment is crucial for managing COPD symptoms and preventing exacerbations.
From the Research
Recommended Dosage of Deviry (Duphaston) Tablet for COPD
There are no research papers to assist in answering this question, as none of the provided studies mention the use of Deviry (Duphaston) tablets for the treatment of Chronic Obstructive Pulmonary Disease (COPD) 2, 3, 4, 5, 6.
Alternative Treatments for COPD
- The management of COPD is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids 4.
- Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists may be used for the treatment of stable COPD 5.
- Medroxyprogesterone may be associated with significant improvements in blood pH, PCO2, dyspnea, and daily duration of noninvasive ventilation using in patients with COPD exacerbation 6.
Key Findings
- Triple therapy (inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists) may reduce rates of moderate-to-severe COPD exacerbations and improve health-related quality of life 5.
- Medroxyprogesterone may improve blood gases and short-term hospital outcomes in patients with COPD treating with noninvasive ventilation 6.